Bridge Creek Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-30,425
Closed -$281K 92
2019
Q2
$281K Buy
30,425
+2,600
+9% +$31.4K 0.14% 83
2019
Q1
$436K Sell
27,825
-675
-2% -$11.9K 0.22% 72
2018
Q4
$439K Sell
28,500
-100
-0.3% -$2.05K 0.25% 70
2018
Q3
$616K Sell
28,600
-107
-0.4% -$2.48K 0.31% 64
2018
Q2
$698K Sell
28,707
-245
-0.8% -$5K 0.37% 63
2018
Q1
$495K Buy
28,952
+125
+0.4% +$2.44K 0.26% 69
2017
Q4
$546K Sell
28,827
-10,870
-27% -$164K 0.27% 65
2017
Q3
$699K Buy
39,697
+8,255
+26% +$186K 0.37% 63
2017
Q2
$1.04M Sell
31,442
-19
-0.1% -$588 0.57% 58
2017
Q1
$1.01M Buy
31,461
+5,750
+22% +$196K 0.56% 58
2016
Q4
$932K Buy
25,711
+442
+2% +$17.6K 0.53% 58
2016
Q3
$1.16M Buy
25,269
+4,665
+23% +$243K 0.67% 55
2016
Q2
$1.03M Buy
20,604
+1,765
+9% +$94K 0.61% 56
2016
Q1
$1.01M Hold
18,839
0.58% 58
2015
Q4
$1.24M Buy
+18,839
New +$1.16M 0.75% 54

Other funds holding TEVA

Bridge Creek Capital Management's TEVA Position: Q3 2019 in Review

Bridge Creek Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2019, closing a stake of 30,425 shares — an estimated $281K sold.

Bridge Creek Capital Management first reported a position in TEVA in Q4 2015 and held it in 15 quarters. The position peaked at $1.24M in Q4 2015. 428 funds tracked by Wall St. Rank hold TEVA as of Q3 2019.

  • Bridge Creek Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2019 after selling out during the quarter.
  • Bridge Creek Capital Management sold 30,425 Teva Pharmaceutical Industries Limited shares in Q3 2019, an estimated $281K.
  • Bridge Creek Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q4 2015 and held it in 15 quarters.
  • Bridge Creek Capital Management's Teva Pharmaceutical Industries Limited position peaked at $1.24M in Q4 2015.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2019.

Based on Bridge Creek Capital Management's 13F filing for Q3 2019, filed 10 Oct 2019.